Remidio Inc., a health technology company dedicated to combating global blindness from conditions such as Diabetic Retinopathy, Glaucoma, AMD, and Cataracts, is on the brink of achieving a significant milestone.

This quarter, Remidio is poised to deploy its 1000th FOP-NM handheld fundus camera to healthcare providers across the United States. Since 2019, these state-of-the-art devices have been instrumental in supporting diabetic retinopathy screening activities for over 3,500 high-volume healthcare providers in the US.

The FOP-NM, hailed as the world's first smartphone-based non-mydriatic fundus camera, has been a game-changer, eliminating the need for patient dilation and rapidly transforming retinal examinations in the US. Its portability and ease of use have garnered widespread acceptance not only within clinic settings but also in university health systems such as the University of Virginia.

Dr. Arjun Dirghangi, Assistant Professor of Ophthalmology at the University of Virginia, lauds the FOP-NM for its user-friendly design and excellent image quality. "Remidio's FOP-NM is easier to use, easy to train on. We have gotten good images, even from trainees who have never used the system before, within 30 seconds to 2 minutes per eye. My goal at the end of the day is to improve access to screening. And this is certainly one of the more powerful tools that I have seen to be able to do that," said Dirghangi.

In a comparative, clinical validation study published in Nature Eye, Remidio's FOP-NM demonstrated image quality on par with the 'gold standard of imaging,' distinguishing itself from other handheld retinal cameras.

Erik Hafkey, Remidio's Chief Commercial Officer, highlights the company's mission to impact the lives of millions at risk for Diabetic Retinopathy in the US. "Our goal is to impact the lives of nearly 30M at risk for Diabetic Retinopathy in the US. New partnerships with proven technologies will be required to reach this goal. Remidio is delighted to open our hardware and telehealth platform for collaboration with AI SaMD companies and care providers working to bring care closer to the patient. As our vision for using retinal imaging, viewing the 'windows to our body', won't end with just eye diseases.  We seek out many other chronic conditions that may be caught early using retinal imaging. The portability, affordability, and ease of use of Remidio devices naturally fit into already existing clinical workflows, enabling this technology to quickly scale its impact," said Hafkey.

Remidio is an ISO 13485-certified medical device company focused on preventing blindness through accessible and user-friendly technologies. Their CE marked and FDA 510k registered medical devices have impacted over 15 million patients in 40+ countries worldwide.